MACROMOLECULAR DRUG CARRIER SYSTEMS IN CANCER-CHEMOTHERAPY - MACROMOLECULAR PRODRUGS

被引:119
作者
TAKAKURA, Y [1 ]
HASHIDA, M [1 ]
机构
[1] KYOTO UNIV,FAC PHARMACEUT SCI,DEPT DRUG DELIVERY RES,SAKYO KU,KYOTO 60601,JAPAN
关键词
D O I
10.1016/1040-8428(94)00131-C
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
[No abstract available]
引用
收藏
页码:207 / 231
页数:25
相关论文
共 210 条
[1]   INHIBITION OF HUMAN-TUMOR GROWTH IN NUDE-MICE BY A CONJUGATE OF DOXORUBICIN WITH MONOCLONAL-ANTIBODIES TO EPIDERMAL GROWTH-FACTOR RECEPTOR [J].
ABOUDPIRAK, E ;
HURWITZ, E ;
BELLOT, F ;
SCHLESSINGER, J ;
SELA, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (10) :3778-3781
[2]   CYTO-TOXIC ACTIVITY OF DAUNORUBICIN OR VINDESIN CONJUGATED TO A MONOCLONAL-ANTIBODY ON CULTURED MCF-7 BREAST-CARCINOMA CELLS [J].
ABOUDPIRAK, E ;
LESUR, B ;
RAO, KSPB ;
BAURAIN, R ;
TROUET, A ;
SCHNEIDER, YJ .
BIOCHEMICAL PHARMACOLOGY, 1989, 38 (04) :641-648
[3]  
ABOUDPIRAK E, 1988, CANCER RES, V48, P3188
[4]   ANTIGEN-SPECIFIC DRUG-TARGETING USED TO MANIPULATE AN IMMUNE-RESPONSE INVIVO [J].
ABUHADID, MM ;
BANKERT, RB ;
MAYERS, GL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (20) :7232-7236
[5]  
AFFECK K, 1992, BRIT J CANCER, V65, P838
[6]  
BAGSHAWE KD, 1991, DIS MARKERS, V9, P233
[7]  
BALLANTYNE KC, 1988, INT J CANCER S, V2, P103
[8]   BIOPHARMACEUTICAL CONSIDERATIONS IN SUBCUTANEOUS AND INTRAMUSCULAR DRUG ADMINISTRATION [J].
BALLARD, BE .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1968, 57 (03) :357-+
[9]   PLASMA-LEVELS OF DOXORUBICIN AFTER IV BOLUS INJECTION AND INFUSION OF THE DOXORUBICIN-DNA COMPLEX IN RABBITS AND MAN - COMPARISON WITH FREE DOXORUBICIN [J].
BAURAIN, R ;
DEPREZDECAMPENEERE, D ;
ZENEBERGH, A ;
TROUET, A .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1982, 9 (02) :93-96
[10]   DEGRADATION OF MITOMYCIN-C IN ACIDIC SOLUTION [J].
BEIJNEN, JH ;
UNDERBERG, WJM .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1985, 24 (2-3) :219-229